Urge Congress to Support the MAT Act

We’re in the midst of a devastating overdose crisis that is worsening due to COVID-19. Yet most people who want help can’t get it, especially those who are incarcerated.

Medications for addiction treatment (MAT), like methadone and buprenorphine, are the most effective intervention for opioid dependency but outdated federal rules make it difficult to access. Buprenorphine is the only medication that requires permission from the Drug Enforcement Administration (DEA) in order for doctors to prescribe it. It’s time to change that. 

Urge Congress to support the MAT Act to remove barriers to buprenorphine treatment critical to reducing drug overdose deaths.

Take Action
Your Message
Dear Member of Congress,

Sincerely,

[First Name] [Last Name]
[Your Address]

* Drug Policy Alliance is committed to protecting your privacy and will never share your email address.

If you sign and have not already registered, you will receive periodic updates and communications from the Drug Policy Alliance.

If you take action and have not already registered, you will receive periodic updates and communications from the Drug Policy Alliance.

If you donate and have not already registered, you will receive periodic updates and communications from the Drug Policy Alliance.